Oropharyngeal cancer: Clinical implications of the HPV connection

Annals of Oncology

Volumn 22, Issue 5, 2011, Pages 997-999

  Psyrri, A ^a   Cohen, E ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; DOCETAXEL; FLUOROURACIL; ONCOPROTEIN; PLATINUM COMPLEX; PROTEIN P53; VIRUS DNA; WART VIRUS VACCINE;

CANCER INCIDENCE; CHEMORADIOTHERAPY; DISEASE ASSOCIATION; EDITORIAL; GENE REPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; OROPHARYNX CARCINOMA; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SQUAMOUS CELL CARCINOMA; TOBACCO; TREATMENT RESPONSE; VIRUS ONCOGENE;

EID: 79955512908     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr124     Document Type: Editorial

References (20)

1. Gillison ML, Koch WM, Capone RB et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92(9): 709-720.
2. Weinberger PM, Yu Z, Haffty BG et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24(5): 736-747.
3. Carbone M, Klein G, Gruber J, Wong M. Modern criteria to establish human cancer etiology. Cancer Res 2004; 64: 5518-5524.
4. D'Souza G, Kreimer AR, Viscidi R et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356(19): 1944-1956.
5. D'Souza G, Zang HH, D'Souza WD et al. Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer. Oral Oncol 2010; 46(2): 100-104.
6. D'Souza G, Agrawal Y, Halpern J et al. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009; 199(9): 1263-1269.
7. Gillison Ml, D'Sousa G, Westra W et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100(6): 407-420.
8. Rampias T, Sasaki C, DiMaio D, Psyrri A. E6/E7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 2009; 101: 412-423.
9. Posner M, Lorche J, Goloubeva O et al. Survival and human papillomavirus in oropharynx cancer in TAX324: a subset analysis from an international phase III trial. Ann Oncol 2011; 22: 1071-1077.
10. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357(17): 1705-1715.
11. Rampias T, Boutati E, Pectasides E et al. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res 2010; 8(3): 433-443.
12. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363(1): 24-35.
13. Rischin D, Young RJ, Fisher R et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28(27): 4142-4148.
14. Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100(4): 261-269.
15. Licitra L, Perrone F, Bossi P et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24(36): 5630-5636.
16. Butz K, Geison C, Ullmann A et al. Cellular responses of HPV-positive cancer cells to genotoxic anticancer agents: repression of E6/E6 oncogene expression and induction of apoptosis. Int J Cancer 1996; 68: 506-513.
17. Yoo GH, Moon J, Leblanc M et al. A phase 2 trial of surgery with perioperative INGN201 (Ad5CMV-p53)gene therapy followed by chemoradiotherapy for advanced, resectable, squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx and larynx: report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg 2009; 135(9): 869-874.
18. Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6(5): 271-278.
19. Villa LL. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine 2006; 24 (Suppl 1): S23-S28.
20. Maeda H, Kubo K, Sugita Y et al. DNA vaccine against hamster oral papillomavirus-associated oral cancer. J Int Med Res 2005; 33(6): 647-653.